(S)-1-(Tert-Butoxycarbonyl)-4-Oxopyrrolidine-2-Carboxylic Acid

For the development of macrocyclic αvβ3 integrin antagonists with sub-nanomolar affinity, introduction of a 4-oxoproline residue into the cyclic peptide backbone forces a β-turn geometry that pre‑organizes the Arg-Gly-Asp pharmacophore. The (S)-1-(tert-butoxycarbonyl)-4-oxopyrrolidine-2-carboxylic acid is first anchored via its C‑2 carboxylate to a chlorotrityl chloride resin loaded at 1.2 mmol/g. On‑resin Boc removal is achieved with 50% TFA in DCM containing 5% triisopropylsilane and 2.5% water at 0 °C for 45 min, during which the 4‑keto group remains intact provided the cocktail is anhydrous after scavenging; traces of water initiate aldol condensation with liberated tert‑butyl cation fragments, generating a resin‑bound β‑hydroxyketone side product detectable by LC‑MS as a +18 Da adduct. Subsequent coupling with Fmoc‑Asp(OtBu)‑OH using HBTU/2.0 M DIPEA in NMP proceeds to >99% conversion by Kaiser test within 30 min. Linear pentapeptide assembly continues with Fmoc‑Gly‑OH and Fmoc‑Arg(Pbf)‑OH, after which side‑chain deprotection with 95% TFA/triisopropylsilane/water (95:2.5:2.5) for 2 h releases the crude linear peptide and simultaneously removes the Pbf group. Cyclisation is performed at 0.5 mM concentration in DMF using PyBOP/HOBt/DIEA (3:3:6 equivalents) for 16 h; the 4‑oxo group does not interfere with carboxyl activation. Reverse‑phase preparative HPLC on a C18 column (250 × 50 mm, 10 µm) with a linear gradient of 20–50% acetonitrile in 0.1% TFA yields the homogeneous cyclic 4‑oxoproline‑RGD peptidomimetic with 98.5% purity by analytical HPLC at 220 nm. In a competitive ELISA against immobilised vitronectin, the resultant macrocycle displays an IC₅₀ of 0.33 nM for αvβ3, compared with 1.8 nM for the analogous proline‑containing congener, confirming the conformational constraint imposed by the 4‑carbonyl. Residual palladium from Arg‑deprotection steps is controlled to <10 ppm per ICH Q3D via a trimercaptotriazine resin scavenging step, and the final product is lyophilised from 0.1% TFA in water to a residual water content of <5% by Karl Fischer titration (USP <921>).

In the stereocontrolled total synthesis of discorhabdin C analogues, the (S)-1-(tert-butoxycarbonyl)-4-oxopyrrolidine-2-carboxylic acid scaffold serves as the sole source of chirality for constructing the pyrroloiminoquinone core. The ketone is first converted to the corresponding oxime by treatment with hydroxylamine hydrochloride (1.2 eq) and sodium acetate (1.5 eq) in methanol at 50 °C for 3 h, giving exclusively the E‑oxime as confirmed by ¹H‑NMR coupling patterns. Reduction of the oxime with Raney® nickel under 4 bar hydrogen in methanol containing 2% aqueous ammonia proceeds at 25 °C over 8 h, affording the 4‑amino derivative as a 4:1 diastereomeric mixture. The desired (2S,4S)‑isomer is enriched by crystallisation of the crude hydrochloride salt from isopropanol/diethyl ether (1:3) at ‑20 °C, improving the diastereomeric ratio to 97:3. The amine is then tosylated (TosCl, 1.05 eq, pyridine, 0 °C) and the Boc group removed with 4 M HCl in dioxane. Subsequent N‑Boc reprotection is performed with Boc₂O/1.1 eq in THF/water at pH 8.5 to avoid simultaneous sulfonamide cleavage. The orthogonally protected amino acid is coupled to a dimethoxyindole fragment using EDC/HOBt (1.2 eq each) in DMF at 0 °C to 20 °C over 12 h. Intramolecular oxidative cyclisation to install the pyrrolo[2,3‑c]quinoline ring system is triggered by phenyliodine(III) bis(trifluoroacetate) (1.3 eq) in hexafluoroisopropanol at ‑10 °C; the reaction is exothermic and requires dosing time of 45 min to keep the internal temperature below ‑5 °C. After aqueous work‑up, global deprotection with 95% TFA/TIPS (95:5, 1 h) delivers the crude discorhabdin analogue, which is purified by silica gel chromatography (CHCl₃/MeOH/NH₄OH, 90:9:1) to yield the bright red alkaloid in 11% overall yield from the 4‑oxoproline building block. The optical rotation is measured at [α]_D²⁰ = −384 (c 0.1, MeOH), consistent with the anticipated absolute configuration. Traces of genotoxic aniline, a possible reduction by‑product, are monitored by GC‑MS (LOD 0.5 ppm) and kept below the threshold of toxicological concern of 1.5 µg/day per ICH M7.

Can a Ketoreductase-Mediated Reduction Deliver >99% de for trans‑4‑Hydroxy‑L‑proline at Multi‑kilo Scale?

Biocatalytic reduction of (S)-1-(tert‑butoxycarbonyl)-4‑oxopyrrolidine-2‑carboxylic acid to (2S,4R)-1‑Boc‑4‑hydroxyproline exploits an engineered ketoreductase (KRED) variant with a substrate coupled cofactor regeneration system. The reaction is seeded with a lyophilised KRED preparation (0.5 g per 100 g substrate), NADP⁺ (0.1 g per 100 g substrate), glucose dehydrogenase (GDH) (0.3 g per 100 g substrate), and D‑glucose (1.5 mol per mol ketone) in 0.1 M potassium phosphate buffer at pH 7.0, maintained at 30.0 ± 0.5 °C in a jacketed stirred‑tank reactor equipped with a Rushton impeller run at 150 rpm. Because the enzyme is susceptible to shear inactivation, the tipspeed is limited to 1.2 m/s. The ketone is introduced as a solid via a Schenk‑type solids addition funnel under a nitrogen blanket, fed in 10 equal portions at 45‑min intervals to avoid substrate inhibition that occurs at dissolved concentrations above 50 g/L; the starting pH is adjusted to 7.0 with 2 M NaOH and held throughout by a pH‑stat delivering the same base. A DO probe is installed not for oxygen demand—the GDH/glucose recycle is anaerobic—but to detect any air ingress that would oxidise the reduced cofactor; the headspace is continuously purged with 0.2 µm filtered nitrogen at 0.5 vvm. Conversion is monitored by chiral SFC (Chiralpak AD‑H, 250 × 4.6 mm, 10% MeOH/CO₂, 2.5 mL/min, 210 nm), showing 99.4% consumption of the ketone within 8 h and a diastereomeric excess of 99.2% for the trans‑configured hydroxyproline. After filtration through a 0.45 µm polyethersulfone membrane to remove particulates, the aqueous phase is acidified to pH 2.0 with 6 M HCl and extracted with ethyl acetate (3 × 500 mL). The combined organic layer is dried over Na₂SO₄ and concentrated to a residue that crystallises from ethyl acetate/heptane (1:3) at −20 °C, yielding 88.3% of white solid. Boc deprotection with 4 M HCl in dioxane at 20 °C for 1.5 h followed by neutralisation with propylene oxide and recrystallisation from ethanol/water affords trans‑4‑hydroxy‑L‑proline with 99.8% ee (Chiralpak ZWIX(+), 0.5 mL/min, H₂O/MeCN 50:50 with 50 mM formic acid, 25 mM diethylamine), meeting the stringent pharmacopoeial requirements for a carbapenem starting material per EP 10.0 monograph 01/2021:1164. Residual solvents are assessed by headspace GC‑FID against ICH Q3C limits: dichloromethane <60 ppm, ethyl acetate <500 ppm, dioxane <380 ppm. Elemental analysis: C 45.78% (calc. 45.80%), H 6.92% (6.92%), N 10.68% (10.68%).

DAST‑Mediated Geminal Difluorination and Its Engineering Constraints

Conversion of the ketone to a 4,4‑difluoro‑L‑proline scaffold proceeds through methyl (S)-1‑Boc‑4‑oxopyrrolidine-2‑carboxylate, prepared by esterification of the parent carboxylic acid with methanol/thionyl chloride (1.2 eq) at 0 °C to 25 °C in 96% yield. The dried ester is dissolved in anhydrous dichloromethane (10 mL/g) under nitrogen and cooled to −78 ± 2 °C in a jacketed reaction calorimeter (Mettler Toledo RC1e) to quantify heat flow during DAST addition. Diethylaminosulfur trifluoride (1.5 eq) is added dropwise over 60 min, maintaining an internal temperature below −72 °C; the exotherm release reaches −720 kJ/kg of DAST. After addition, the mixture is allowed to warm to 0 °C over 4 h under continuous stirring and then quenched onto ice‑cold saturated NaHCO₃. The biphasic mixture is filtered through a Celite pad to remove insoluble tar, and the organic layer is washed with brine and concentrated. Flash chromatography on silica gel (particle size 40–63 µm) with ethyl acetate/hexane (1:9 to 1:4) isolates methyl (S)-1‑Boc‑4,4‑difluoropyrrolidine-2‑carboxylate as a pale yellow oil in 48 – 55% yield. A major side reaction is elimination to form the 3,4‑dehydropyrrolidine, which elutes just ahead of the product and must be separated with a column height of ≥ 25 cm and a loading of ≤ 10 g crude per 100 g silica. Premature warming to above −70 °C during DAST dosing increases the elimination by‑product to 30–40% and reduces the difluorinated product to <35%. Hydrolysis of the methyl ester with 1.05 eq of LiOH·H₂O in THF/water (3:1) at 0 °C for 2 h is critical: stronger basic conditions (NaOH, >5 °C) provoke racemisation at the C‑2 centre and decomposition of the acid‑labile Boc group. After acidification to pH 2 with 2 M HCl and extraction with ethyl acetate, the Boc‑protected difluoro acid is crystallised from diisopropyl ether to yield 91% recovery with 98.6% ee (Chiralcel OD‑H, hexane/IPA/TFA 95:5:0.1). The chiral intermediate is supplied as a controlled starting material for a BACE1 inhibitor programme; each batch is screened for genotoxic sulfonate esters (mesylate, tosylate) by LC‑MS/MS to ensure levels <1.5 µg/day in the hypothetical final dosage form, consistent with ICH M7 Class 2A thresholds.

Ketoamide Warhead Construction for NS3/4A Protease Inhibitors

The electrophilic ketoamide warhead found in several acyclic and macrocyclic hepatitis C protease inhibitors is accessed from (S)-1-(tert‑butoxycarbonyl)-4-oxopyrrolidine-2-carboxylic acid through a protection–coupling–deprotection sequence that preserves the stereochemical integrity at C‑2. Initially, the 4‑oxo group is masked as a 1,3‑dioxolane by refluxing the methyl ester with ethylene glycol (5 eq) and p‑toluenesulfonic acid monohydrate (0.05 eq) in toluene using a Dean‑Stark trap; complete water removal is reached within 3 h, yielding 96% conversion. Saponification with 1 M NaOH in methanol/water (4:1) at 20 °C for 1 h liberates the free acid, isolated by acid‑base extraction in 93% yield. The acid is pre‑activated with HATU (1.05 eq) and DIPEA (2.5 eq) in DMF and coupled to a vinylcyclopropane‑containing peptide amine fragment at 0 °C for 30 min, then at room temperature for 2 h. The resulting amide is exposed to 4 M HCl in dioxane to cleave both the Boc and the ketal simultaneously over 1.5 h; the liberated ketone is immediately oxidised with Dess‑Martin periodinane (1.2 eq, wet DCM, 0.5% H₂O) to furnish the α‑ketoamide in a one‑pot manner. Aqueous work‑up with 10% Na₂S₂O₃ then NaHCO₃ affords the crude ketoamide, which is purified by normal‑phase chromatography (CH₂Cl₂/MeOH, 97:3) to give the final NS3/4A inhibitor scaffold in 61% overall yield from the ketal acid. Process analytical technology (PAT) employs an inline ReactIR probe to monitor disappearance of the characteristic ketone stretch at 1715 cm⁻¹ during ketal formation and its reappearance at 1738 cm⁻¹ upon deprotection, confirming full regeneration of the 4‑oxo group without enol ether formation. The critical impurity is the des‑keto alcohol, which arises from over‑reduction during hydrogenolytic deprotection of a benzyl ester present in the peptide fragment, and is limited to <0.15% by LC‑MS (SIM m/z 492.2). The final ketoamide is amorphous and stored under argon at −20 °C; its moisture sensitivity requires handling under inert atmosphere with <100 ppm H₂O in the glovebox.

When Bucherer–Bergs Cyclization Competes with Racemization at C‑2

Transformation of the 4‑ketone into a spirohydantoin expands the utility of the building block toward soluble epoxide hydrolase (sEH) inhibitors. The one‑pot Bucherer–Bergs reaction combines the methyl ester of (S)-1‑Boc‑4‑oxopyrrolidine-2‑carboxylic acid with potassium cyanide (1.5 eq) and ammonium carbonate (4.0 eq) in ethanol/water (1:1) at 60 °C. During the initial 30 min, the pH rises to 9.2; this alkaline regime accelerates racemisation via enolate formation at the α‑carbon adjacent to the carbomethoxy group. To suppress erosion of enantiopurity, the reaction is formulated with 0.5 eq of powdered ammonium chloride to buffer the mixture near pH 8.2, and the cyanide is added as a 3 M aqueous solution via syringe pump over 90 min while maintaining the temperature at 58–60 °C. After stirring for a further 1 h, TLC (silica, ethyl acetate/hexane 1:1, visualised with ninhydrin) indicates complete consumption of the ketone. The cooled mixture is neutralised with 2 M HCl to pH 6.5, and the precipitated spirohydantoin is collected and washed extensively with water to remove inorganic salts. Recrystallisation from isopropanol yields the pure (S)‑configured hydantoin as colourless plates in 67% yield. Chiral HPLC analysis (Chiralpak IA, hexane/ethanol 95:5, 1.0 mL/min) reveals an enantiomeric ratio of 98.3:1.7; the residual enantiomer co‑elutes with a by‑product formed from cyanohydrin oxidation and is controlled to <0.5 area% in the final drug substance synthetic pathway. Biological evaluation of the corresponding N‑Boc‑deprotected spirohydantoin shows an IC₅₀ of 22 nM against recombinant human sEH in a fluorescence‑based assay using PHOME as substrate (λ_ex 330 nm, λ_em 465 nm). Process safety testing of the cyanide‑containing stream is conducted by adiabatic calorimetry (ARC) to rule out exothermic degradation above 100 °C, and the waste is destroyed with 15% sodium hypochlorite at pH >11 for 4 h before disposal, validating CN⁻ to <1 ppm by ion‑selective electrode.